• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Tilray, Inc. (Amendment)

    5/25/21 5:03:22 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $TLRY alert in real time by email
    SC 13D/A 1 brhc10025106_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13D
     
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)*
     
    Tilray, Inc.
    (Name of Issuer)
     
    Class 2 Common Stock
    (Title of Class of Securities)
     
    88688T 100
    (CUSIP Number)
     
    Brendan Kennedy
    c/o Tilray, Inc.
    745 Fifth Avenue, Suite 1602
    New York, NY 10151
    Telephone: (519) 322-8800
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
    April 30, 2021
    (Date of Event Which Requires Filing of This Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
     
     
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 88688T 100
    1
    NAMES OF REPORTING PERSONS
     
     
    Brendan Kennedy
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    12,837,819
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    12,837,819
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    12,837,819 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    2.9%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     
    (1)
    Consists of (1) 9,974,196 shares of Class 2 Common Stock, par value $0.0001 per share (the “Common Stock”) held directly by Mr. Kennedy, (2) 2,628,683 shares of Common Stock that are issuable upon the exercise of options held directly by Mr. Kennedy that are exercisable within 60 days of May 25, 2021, and (3) 234,940 shares of Common Stock held directly by a limited liability company, of which Mr. Kennedy is the sole member and has sole voting and investment power decisions as it relates to such limited liability company.
     
    (2)
    This calculation is based on 447,371,310 shares of Common Stock outstanding as of May 7, 2021, as reported in the Prospectus Supplement on Form 424(b)(7) filed by Tilray, Inc. (the “Issuer”) on May 13, 2021.
     

    This Amendment No. 5 to Schedule 13D (“Amendment No. 5”) relates to the Schedule 13D filed on December 23, 2019 (as amended and supplemented through the date of this Amendment No. 5, the “Schedule 13D”) by Brendan Kennedy (the “Reporting Person”) relating to the Issuers’ Common Stock. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D. Except as specifically amended by this Amendment No. 5, the Schedule 13D is unchanged.

    Item 1.
    Security and Issuer
     
    The Reporting Person is filing this Amendment No. 5 to report that, following certain transactions in connection with the closing of the plan of arrangement (the “Arrangement”) between Tilray, Inc. and Aphria Inc. on April 30, 2021, he ceased to own five percent or more of the Issuer’s outstanding Common Stock.
     
    This Amendment No. 5 is also being filed to report that the Issuer’s principal executive offices has changed to 745 Fifth Avenue, Suite 1602, New York, NY 10151.
     
    Item 2.
    Identity and Background
     
    Item 2(b) of the Schedule 13D is hereby amended and restated as follows:
     
    “(b)
    Residence or business address:
     
    The address of the Reporting Person’s principal place of business is:
     
    c/o Tilray, Inc.
    745 Fifth Avenue, Suite 1602
    New York, NY 10151”
     
    Item 4.
    Purpose of Transaction
     
    Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following information:
     
    “In connection with the closing of the Arrangement, all of the Reporting Person’s outstanding restricted stock units (“RSUs”) vested and settled in shares of Common Stock of the Issuer, and following subsequent withholdings of the vested shares of Common Stock to satisfy tax obligations, the Reporting Person ceased to own five percent or more of the Issuer’s outstanding Common Stock.”
     
    Item 5.
    Interest in Securities of the Issuer

    Item 5 of the Schedule 13D is hereby amended and supplemented by adding the following information:

    “(a), (b)
    The Reporting Person beneficially owns 12,837,819 shares of the Issuer’s Common Stock, which represents 2.9% of the outstanding Common Stock, based on information contained in the Issuer’s Prospectus Supplement on Form 424(b)(7) filed on May 13, 2021. The Reporting Person has sole voting and dispositive power over all such shares. 2,628,683 of the Reporting Person’s shares beneficially owned represent shares of Common Stock underlying vested stock options exercisable by the Reporting Person within sixty days of the date of this Amendment No. 5, and 234,940 shares of Common Stock are held directly by a limited liability company, of which Mr. Kennedy is the sole member and has sole voting and investment power decisions as it relates to such limited liability company.


    (c)
    Information with respect to the Reporting Person’s transactions involving the Common Stock effected within the past sixty days is set forth below:

    Date of Transaction
    Type of Transaction
    Quantity
    Class of Stock
    Price Per Share
    (excluding
    commissions)
             
    April 17, 2021
    Vesting of RSUs
    37,020
    Class 2 Common Stock
    N/A
             
    April 17, 2021
    Withholding of Common Stock to satisfy tax obligations
    14,568
    Class 2 Common Stock
    17.20
             
    April 30, 2021
    Vesting of RSUs
    73,954
    Class 2 Common Stock
    N/A
             
    April 30, 2021
    Vesting of RSUs
    76,000
    Class 2 Common Stock
    N/A
             
    May 3, 2021
    Withholding of Common Stock to satisfy tax obligations
    32,148
    Class 2 Common Stock
    $16.99
             
    May 3, 2021
    Withholding of Common Stock to satisfy tax obligations
    33,037
    Class 2 Common Stock
    $16.99
     
    (e)
    Upon the closing of the Arrangement and the vesting of the Reporting Person’s RSUs into shares of Common Stock, and the withholding of a portion of the shares to satisfy the Reporting Person’s tax obligations, the Reporting Person ceased to beneficially own more than five percent of the Issuer’s outstanding Common Stock.”


    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: May 25, 2021
    By:
     
    /s/ Brendan Kennedy
         
    Brendan Kennedy



    Get the next $TLRY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TLRY

    DatePrice TargetRatingAnalyst
    4/5/2024$2.25 → $2.75Neutral
    Alliance Global Partners
    11/2/2022$3.90Mkt Perform
    Bernstein
    7/29/2022$3.00Hold → Sell
    The Benchmark Company
    3/4/2022$9.00Hold → Buy
    Canaccord Genuity
    1/11/2022$7.40 → $6.90Neutral
    Cantor Fitzgerald
    1/7/2022$11.80 → $7.40Neutral
    Cantor Fitzgerald
    11/18/2021$10.00Underweight
    Barclays
    11/1/2021$18.00 → $11.80Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $TLRY
    SEC Filings

    See more
    • SEC Form 10-K filed by Tilray Brands Inc.

      10-K - Tilray Brands, Inc. (0001731348) (Filer)

      7/28/25 7:22:54 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Tilray Brands, Inc. (0001731348) (Filer)

      7/28/25 4:32:41 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

      8-K - Tilray Brands, Inc. (0001731348) (Filer)

      6/23/25 4:10:42 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Simon Irwin D bought $100,106 worth of shares (165,000 units at $0.61), increasing direct ownership by 4% to 3,941,633 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      7/30/25 6:52:32 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Merton Carl A bought $19,939 worth of shares (33,500 units at $0.60), increasing direct ownership by 4% to 798,069 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      7/30/25 3:12:46 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Merton Carl A bought $35,360 worth of shares (26,000 units at $1.36) (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      11/18/24 11:29:05 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tilray Brands Reports Fourth Quarter and Fiscal 2025 Financial Results

      Fiscal Year Net Revenue of $821 Million, $834 Million in Constant Currency, Strategic Decisions Impacted Revenue by $35 Million Q4 Consolidated Adjusted EBITDA is the 2nd Highest in the Company's History International Cannabis Revenue Increased 71% in Q4 and 19% for the Fiscal Year; Canadian Cannabis Remained #1 by Revenue in the Fiscal Year; Global Cannabis Gross Margin Increased by ~700 Basis Points in the Fiscal Year 19% Revenue Growth in Tilray Beverages with $241 Million for the Fiscal Year 9% Revenue Growth in Tilray Wellness with $60 Million for the Fiscal Year Strong Balance Sheet with $256 Million Available in Cash and Marketable Securities; Total Debt Repayments of ~$100 Milli

      7/28/25 4:30:13 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Award-Winning Breckenridge Distillery Makes Bold Entry into Tequila with Launch of Casa Breck

      BRECKENRIDGE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), proudly celebrates International Tequila Day with the launch of Casa Breck Tequila - a bold leap into a new spirits category. Crafted with reverence for tradition and inspired by cross-cultural storytelling, Casa Breck represents a striking fusion of the Rocky Mountains' rugged spirit and the vibrant heart of Jalisco, Mexico. Photo Courtesy: Breckenridge Distillery Casa Breck Blanco and Casa Breck Reposado are the first offerings in this new line, each one a tribute to the time-honored craftsmanship of

      7/24/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Breckenridge Distillery Launches Mock One: Bold, Premium Non-Alcoholic Alternatives to Whiskey, Tequila, Gin & Rum - Crafted for Everyone Who Loves a Great Drink

      BRECKENRIDGE, Colo., July 17, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), is pleased to announce the launch of Mock One, a new line of non-alcoholic spirits. Mock One is not just another non-alcoholic spirit - it's crafted by the team behind one of the most awarded craft distilleries in the United States. Backed by the expertise of the renowned Breckenridge Distillery, recipient of nine Icons of Whisky awards for excellence in quality, innovation, branding, and taste, Mock One brings the same uncompromising standards to the zero-proof category with spirit alternatives inspired by their

      7/17/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners reiterated coverage on Tilray with a new price target

      Alliance Global Partners reiterated coverage of Tilray with a rating of Neutral and set a new price target of $2.75 from $2.25 previously

      4/5/24 7:39:50 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bernstein initiated coverage on Tilray with a new price target

      Bernstein initiated coverage of Tilray with a rating of Mkt Perform and set a new price target of $3.90

      11/2/22 6:37:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray downgraded by The Benchmark Company with a new price target

      The Benchmark Company downgraded Tilray from Hold to Sell and set a new price target of $3.00

      7/29/22 7:19:40 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Simon Irwin D bought $100,106 worth of shares (165,000 units at $0.61), increasing direct ownership by 4% to 3,941,633 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      7/30/25 6:52:32 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Merton Carl A bought $19,939 worth of shares (33,500 units at $0.60), increasing direct ownership by 4% to 798,069 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      7/30/25 3:12:46 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • President and CEO Simon Irwin D exercised 1,178,109 shares at a strike of $0.41 and covered exercise/tax liability with 647,960 shares, increasing direct ownership by 16% to 3,776,633 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      6/4/25 5:01:34 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Financials

    Live finance-specific insights

    See more
    • Tilray Brands Reports Fourth Quarter and Fiscal 2025 Financial Results

      Fiscal Year Net Revenue of $821 Million, $834 Million in Constant Currency, Strategic Decisions Impacted Revenue by $35 Million Q4 Consolidated Adjusted EBITDA is the 2nd Highest in the Company's History International Cannabis Revenue Increased 71% in Q4 and 19% for the Fiscal Year; Canadian Cannabis Remained #1 by Revenue in the Fiscal Year; Global Cannabis Gross Margin Increased by ~700 Basis Points in the Fiscal Year 19% Revenue Growth in Tilray Beverages with $241 Million for the Fiscal Year 9% Revenue Growth in Tilray Wellness with $60 Million for the Fiscal Year Strong Balance Sheet with $256 Million Available in Cash and Marketable Securities; Total Debt Repayments of ~$100 Milli

      7/28/25 4:30:13 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on July 28, 2025

      NEW YORK and LEAMINGTON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that the Company will release its financial results for the fourth quarter and full fiscal year ended May 31, 2025, after market close on Monday, July 28, 2025. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 4:30 PM Eastern Time. The webcast can be accessed on the Events & Presentations section of Tilray's Investor Relations websi

      7/9/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands Reports Q3 Fiscal 2025 Financial Results

      Tilray Confirms No Current Impact of Tariffs Generated Net Revenue of $186 Million in the Third Quarter, $193 Million in Constant Currency; Strategic Initiatives and SKU Rationalization Impacted Revenue by $13 Million Tilray Beverage Expands U.S. Distribution of Hemp-Derived THC Drinks Across 10 States, Increases Project 420 Cost Savings Plan to $33 Million Tilray Cannabis Increased Gross Margins by 800 bps, Remains the Leader in Canada by Sales Performance, and Generates Strong Sales Growth in Germany Strengthens Balance Sheet with Convertible Note Reduction of $58 Million and Total Debt Reduction of $71 Million, $248 Million Available in Cash and Marketable Securities NEW Y

      4/8/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Leadership Updates

    Live Leadership Updates

    See more
    • Terrapin Beer Co. Celebrates 20 Years of Iconic Wake-n-Bake Beer with Exciting Wake-n-Bake Off Event in Athens, GA

      ATHENS, Ga., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Terrapin Beer Co., a Tilray Beverages craft beer brand under Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), is excited to announce the 20th anniversary of its Wake-n-Bake Coffee Oatmeal Imperial Stout seasonal beer and the annual Wake-n-Bake Off event on Sunday, January 26th, 2025, at the Terrapin taproom in Athens, GA. In celebration of its 20th anniversary, guests will have the chance to observe local restaurants competing to craft the finest dish featuring Terrapin's renowned Wake-n-Bake Beer. This event highlights culinary innovation and fosters community engagement through an array of sweet and savory tastings that showcase the rich flavor

      1/23/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Blue Point Brewing Launches Big Mo Brew to Raise Funds and Awareness for Men's Health During Movember

      PATCHOGUE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Blue Point Brewing Company, Long Island's original craft brewery and subsidiary of Tilray Brands, (NASDAQ:TLRY, TSX:TLRY), is proud to announce the continuation of its men's health awareness campaign in support of Movember. The month shines a light on key men's health issues—mental health, prostate cancer, and testicular cancer—encouraging open conversations and proactive engagement. To honor the initiative, Blue Point Brewing announced the special release of its classic double IPA, Big Mo, available at our brewery and retailers in Long Island, New York. This hazy double IPA, featuring prominent mosaic hops and an ABV of 8.0%, proud

      10/22/24 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Breckenridge Brewery Opens New Location in Fort Collins, Colorado

      FORT COLLINS, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery, a Colorado-based craft brewer with over 30 years of experience brewing approachable, well-balanced beers, announces the opening of its new brewery location in Fort Collins. With doors opening in early August 2024, the new 10,000-square-foot Breckenridge Brewery offers a full restaurant experience and a new vibrant atmosphere in the heart of Fort Collins for all to enjoy. The new location will be a full-service restaurant, upholding the Breckenridge Brewery legacy while ushering in new opportunities for innovation and community collaboration. With a menu boasting a diverse range of culinary delights designed to co

      8/5/24 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Tilray Brands Inc. (Amendment)

      SC 13G/A - Tilray Brands, Inc. (0001731348) (Subject)

      2/13/23 1:34:44 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Tilray Brands Inc.

      SC 13G - Tilray Brands, Inc. (0001731348) (Subject)

      2/10/23 4:41:36 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Tilray Brands Inc.

      SC 13D - Tilray Brands, Inc. (0001731348) (Filed by)

      7/22/22 4:30:22 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care